Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5430905 | 0.87 | PKM (0.50) | LMNAALDH1A1SMN1; SMN2HTR6KMT2A | |
| SCHEMBL5421824 | 0.87 | HTR6 (0.44) | LMNAALDH1A1SMN1; SMN2EPHX2HTR6 | |
| SCHEMBL5439699 | 0.87 | ALDH1A1 (0.55) | LMNAALDH1A1MAPTHTR6KMT2A | |
| SCHEMBL5422812 | 0.85 | ALDH1A1 (0.47) | LMNAALDH1A1MAPTHTR6KMT2A | |
| SCHEMBL5783207 | 0.85 | HTR6 (0.51) | LMNAMAPTNPC1RAB9AHTR6 | |
| SCHEMBL5423668 | 0.84 | SMN1; SMN2 (0.46) | LMNAALDH1A1MAPTSMN1; SMN2EPHX2 | |
| SCHEMBL5419843 | 0.83 | TP53 (0.45) | LMNAALDH1A1MAPTSMN1; SMN2HTR6 | |
| SCHEMBL5781991 | 0.83 | SMN1; SMN2 (0.50) | LMNAALDH1A1MAPTSMN1; SMN2HTR6 | |
| SCHEMBL5426195 | 0.82 | SMN1; SMN2 (0.43) | LMNAALDH1A1MAPTSMN1; SMN2HTR6 | |
| SCHEMBL3152681 | 0.82 | HTR6 (0.65) | LMNAALDH1A1MAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | claimed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | LMNA 3123/4885ALDH1A1 1597/4885MAPT 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.